Editor's Note
August 2014

Restricting Interactions With Industry to Promote Evidence-Based Prescribing

Author Affiliations

Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Intern Med. 2014;174(8):1290. doi:10.1001/jamainternmed.2014.1862

Over the past 15 years, interactions between physicians and the pharmaceutical and medical device industries have received ever greater scrutiny. While the benefits of research collaboration have always been recognized, there are growing concerns that financial relationships are threatening the integrity of research, professional education, patient care, and the public’s trust in medicine. The Association of American Medical Colleges and the Institute of Medicine released statements calling for strengthening the policies governing these interactions, particularly among academic medical centers and professional societies, and requiring transparency and disclosure of financial relationships. In 2007, the American Medical Student Association, in collaboration with the Pew Charitable Trusts, released its “PharmFree Scorecard” that graded medical schools on the presence or absence of a policy regulating interactions between their students and faculty and the pharmaceutical and medical device industries.

First Page Preview View Large
First page PDF preview
First page PDF preview